Prelude Therapeutics (PRLD) Assets Average (2020 - 2026)
Prelude Therapeutics (PRLD) posted Assets Average of $130.5 million for Q1 2026, up 10.54% sequentially from $118.0 million in Q4 2025, and down 17.62% YoY from $158.4 million in Q1 2025.
Prelude Therapeutics (PRLD) Assets Average (2020 - 2026) Analysis & Trends
Prelude Therapeutics has reported Assets Average for 7 years, with the latest figure at $130.5 million in Q1 2026.
- Quarterly Assets Average fell 17.62% year-over-year to $130.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $130.5 million (down 17.62% YoY) and the FY2025 annual result came in at $158.4 million, down 30.09% from the prior year.
- Assets Average improved to $130.5 million in Q1 2026 per PRLD's latest filing, from $118.0 million in the prior quarter.
- Over five years, Assets Average peaked at $292.9 million in Q1 2022 and troughed at $104.8 million in Q3 2025.
- A 5-year average of $209.8 million and a median of $231.4 million in 2022 frame the typical range for Assets Average.
- The sharpest annual moves came in 2024 and 2025: Assets Average grew 25.3% in 2024, then tumbled 50.26% in 2025.
- Over 5 years, Assets Average stood at $231.4 million in 2022, then rose by 15.85% to $268.1 million in 2023, then tumbled by 30.48% to $186.4 million in 2024, then slumped by 36.67% to $118.0 million in 2025, then grew by 10.54% to $130.5 million in 2026.
- According to Business Quant data, Assets Average over the past three periods registered $130.5 million, $118.0 million, and $104.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 3.29 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.86 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 16.08 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.34 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.09 Bn |
| 10 | Prelude Therapeutics | 442.91 Mn | 162.28 Mn | - | 154.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 154.50 Mn |
| Mar 31, 2026 | 130.48 Mn |
| Dec 31, 2025 | 118.04 Mn |
| Sep 30, 2025 | 104.84 Mn |
| Jun 30, 2025 | 128.09 Mn |
| Mar 31, 2025 | 158.39 Mn |
| Dec 31, 2024 | 186.37 Mn |
| Sep 30, 2024 | 210.76 Mn |
| Jun 30, 2024 | 235.70 Mn |
| Mar 31, 2024 | 262.39 Mn |
| Dec 31, 2023 | 268.09 Mn |
| Sep 30, 2023 | 269.56 Mn |
| Jun 30, 2023 | 239.47 Mn |
| Mar 31, 2023 | 209.41 Mn |
| Dec 31, 2022 | 231.41 Mn |
| Sep 30, 2022 | 250.69 Mn |
| Jun 30, 2022 | 269.86 Mn |
| Mar 31, 2022 | 292.88 Mn |
| Dec 31, 2021 | 318.16 Mn |
| Sep 30, 2021 | 340.40 Mn |